{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:55:49Z","timestamp":1791928549802,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00210-025-04032-y","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T21:06:47Z","timestamp":1743109607000},"page":"11161-11178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Circular RNAs: driving forces behind chemoresistance and immune evasion in bladder cancer"],"prefix":"10.1007","volume":"398","author":[{"given":"Mohamed J.","family":"Saadh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael Sheet","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Fawzi","family":"Al-Hussainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Bishoyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Rekha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Kundlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kavitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Aminov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sada Ghalib","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"4032_CR1","doi-asserted-by":"publisher","first-page":"104066","DOI":"10.1016\/j.drudis.2024.104066","volume":"29","author":"G Aquino-Jarquin","year":"2024","unstructured":"Aquino-Jarquin G (2024) CircRNA knockdown based on antisense strategies. Drug Discov Today. 29:104066","journal-title":"Drug Discov Today."},{"issue":"1","key":"4032_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10565-024-09907-z","volume":"40","author":"M Bayat","year":"2024","unstructured":"Bayat M, Nahand JS (2024) Let\u2019s make it personal: CRISPR tools in manipulating cell death pathways for cancer treatment. Cell Biol Toxicol 40(1):61","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"4032_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12943-024-02081-0","volume":"23","author":"M Bayat","year":"2024","unstructured":"Bayat M, Sadri NJ (2024) Exosomal miRNAs: the tumor\u2019s trojan horse in selective metastasis. Mol Cancer 23(1):167","journal-title":"Mol Cancer"},{"issue":"6","key":"4032_CR4","doi-asserted-by":"publisher","first-page":"189179","DOI":"10.1016\/j.bbcan.2024.189179","volume":"1879","author":"M Bayat","year":"2024","unstructured":"Bayat M, Golestani S, Motlaghzadeh S, Bannazadeh Baghi H, Lalehzadeh A, Sadri Nahand J (2024) War or peace: viruses and metastasis. Biochim Biophys Acta Rev Cancer 1879(6):189179","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"8","key":"4032_CR5","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.18632\/aging.101520","volume":"10","author":"J Bi","year":"2018","unstructured":"Bi J, Liu H, Cai Z, Dong W, Jiang N, Yang M et al (2018) Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p\/RAB27A axis. Aging 10(8):1964","journal-title":"Aging"},{"issue":"8","key":"4032_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1182\/blood.2019004260","volume":"138","author":"S Chen","year":"2021","unstructured":"Chen S, Benbarche S, Abdel-Wahab O (2021) Splicing factor mutations in hematologic malignancies. Blood 138(8):599\u2013612","journal-title":"Blood"},{"key":"4032_CR7","doi-asserted-by":"publisher","first-page":"666863","DOI":"10.3389\/fcell.2021.666863","volume":"9","author":"F Cheng","year":"2021","unstructured":"Cheng F, Zheng B, Si S, Wang J, Zhao G, Yao Z et al (2021) The roles of CircRNAs in bladder cancer: biomarkers, tumorigenesis drivers, and therapeutic targets. Front Cell Dev Biol 9:666863","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"4032_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4149\/neo_2018_180318N185","volume":"66","author":"BJ Chi","year":"2019","unstructured":"Chi BJ, Zhao DM, Liu L, Yin XZ, Wang FF, Bi S et al (2019) Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance. Neoplasma 66(2):197\u2013202","journal-title":"Neoplasma"},{"issue":"2","key":"4032_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/kjm2.12306","volume":"37","author":"CJ Cho","year":"2021","unstructured":"Cho CJ, Yu CP, Wu CL, Ho JY, Yang CW, Yu DS (2021) Decreased drug resistance of bladder cancer using phytochemicals treatment. Kaohsiung J Med Sci 37(2):128\u2013135","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"4032_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","volume":"69","author":"PL Crispen","year":"2020","unstructured":"Crispen PL, Kusmartsev S (2020) Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother 69(1):3\u201314","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"4032_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/medicina57080749","volume":"57","author":"J Dobruch","year":"2021","unstructured":"Dobruch J, Oszczud\u0142owski M (2021) Bladder cancer: current challenges and future directions. Medicina 57(8):749","journal-title":"Medicina"},{"issue":"7","key":"4032_CR12","doi-asserted-by":"publisher","first-page":"e18225","DOI":"10.1111\/jcmm.18225","volume":"28","author":"C Dong","year":"2024","unstructured":"Dong C, Hui P, Wu Z, Li J, Man X (2024) CircRNA LOC729852 promotes bladder cancer progression by regulating macrophage polarization and recruitment via the miR-769-5p\/IL-10 axis. J Cell Mol Med 28(7):e18225","journal-title":"J Cell Mol Med"},{"issue":"18","key":"4032_CR13","first-page":"1402","volume":"38","author":"WW Du","year":"2017","unstructured":"Du WW, Yang W, Chen Y, Wu Z-K, Foster FS, Yang Z et al (2017) Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J 38(18):1402\u20131412","journal-title":"Eur Heart J"},{"issue":"1","key":"4032_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J et al (2023) Bladder cancer. Nature Rev Dis Primers 9(1):58","journal-title":"Nature Rev Dis Primers"},{"issue":"5","key":"4032_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3(5):436\u2013443","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"4032_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10565-022-09715-3","volume":"39","author":"D Feng","year":"2023","unstructured":"Feng D, Lv J, Li K, Cao Q, Han J, Yu H et al (2023) CircZNF609 promotes bladder cancer progression and inhibits cisplatin sensitivity via miR-1200\/CDC25B pathway. Cell Biol Toxicol 39(5):1\u201318","journal-title":"Cell Biol Toxicol"},{"issue":"3","key":"4032_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/epi-2019-0295","volume":"12","author":"X Geng","year":"2020","unstructured":"Geng X, Jia Y, Zhang Y, Shi L, Li Q, Zang A et al (2020) Circular RNA: Biogenesis, degradation, functions and potential roles in mediating resistance to anticarcinogens. Epigenomics 12(3):267\u2013283","journal-title":"Epigenomics"},{"issue":"2","key":"4032_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1152\/physrev.00008.2020","volume":"101","author":"KF Goliwas","year":"2021","unstructured":"Goliwas KF, Deshane JS, Elmets CA, Athar M (2021) Moving immune therapy forward targeting TME. Physiol Rev 101(2):417\u2013425","journal-title":"Physiol Rev"},{"key":"4032_CR19","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.2147\/IJN.S461289","volume":"19","author":"R Han","year":"2024","unstructured":"Han R, Rao X, Zhou H, Lu L (2024) Synergistic immunoregulation: harnessing CircRNAs and PiRNAs to amplify PD-1\/PD-L1 inhibition therapy. Int J Nanomed. 19:4803\u201334","journal-title":"Int J Nanomed."},{"key":"4032_CR20","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.2147\/CMAR.S263083","volume":"12","author":"W Huang","year":"2020","unstructured":"Huang W, Lu Y, Wang F, Huang X, Yu Z (2020) Circular RNA circRNA_103809 accelerates bladder cancer progression and enhances chemo-resistance by activation of miR-516a-5p\/FBXL18 axis. Cancer Manag Res 12:7561\u20138","journal-title":"Cancer Manag Res"},{"issue":"9","key":"4032_CR21","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.7150\/ijbs.96671","volume":"20","author":"C Huang","year":"2024","unstructured":"Huang C, Yang Y, Wang X, Chen S, Liu Z, Li Z et al (2024) PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer. Int J Biol Sci 20(9):3570\u20133589","journal-title":"Int J Biol Sci"},{"issue":"4","key":"4032_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.gendis.2015.07.003","volume":"2","author":"Y Jia","year":"2015","unstructured":"Jia Y, Xie J (2015) Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes Dis 2(4):299\u2013306","journal-title":"Genes Dis"},{"issue":"17","key":"4032_CR23","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.7150\/jca.58182","volume":"12","author":"M-P Jiang","year":"2021","unstructured":"Jiang M-P, Xu W-X, Hou J-C, Xu Q, Wang D-D, Tang J-H (2021a) The emerging role of the interactions between circular RNAs and RNA-binding proteins in common human cancers. J Cancer 12(17):5206","journal-title":"J Cancer"},{"issue":"4","key":"4032_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021b) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22(4):266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4032_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01406-7","volume":"20","author":"W Jiang","year":"2021","unstructured":"Jiang W, Pan S, Chen X, Wang Z-w, Zhu X (2021c) The role of lncRNAs and circRNAs in the PD-1\/PD-L1 pathway in cancer immunotherapy. Mol Cancer. 20:1\u201317","journal-title":"Mol Cancer."},{"key":"4032_CR26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","volume":"9","author":"M Joseph","year":"2019","unstructured":"Joseph M, Enting D (2019) Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications. Front Oncol 9:1270","journal-title":"Front Oncol"},{"issue":"6","key":"4032_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/em.22561","volume":"64","author":"M Ju","year":"2023","unstructured":"Ju M, Wu W, Qu J, Sun Y, Li J (2023) Downregulation of circular RNA hsa_circ_0087856 sensitizes bladder cancer cells to cisplatin through targeting miR-1184\/CITED2 signaling. Environ Mol Mutagen 64(6):342\u2013353","journal-title":"Environ Mol Mutagen"},{"issue":"10061","key":"4032_CR28","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstr\u00f6m P-U, Choi W et al (2016) Bladder cancer. Lancet 388(10061):2796\u20132810","journal-title":"Lancet"},{"key":"4032_CR29","doi-asserted-by":"publisher","first-page":"105503","DOI":"10.1016\/j.micpath.2022.105503","volume":"166","author":"A Khatami","year":"2022","unstructured":"Khatami A, Nahand JS, Kiani SJ, Khoshmirsafa M, Moghoofei M, Khanaliha K et al (2022) Human papilloma virus (HPV) and prostate cancer (PCa): The potential role of HPV gene expression and selected cellular MiRNAs in PCa development. Microb Pathog 166:105503","journal-title":"Microb Pathog"},{"key":"4032_CR30","doi-asserted-by":"publisher","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","volume":"13","author":"SK Kim","year":"2022","unstructured":"Kim SK, Cho SW (2022) The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol 13:868695","journal-title":"Front Pharmacol"},{"issue":"9","key":"4032_CR31","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.15252\/embr.201643581","volume":"18","author":"Y Li","year":"2017","unstructured":"Li Y, Zheng F, Xiao X, Xie F, Tao D, Huang C et al (2017) CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep 18(9):1646\u20131659","journal-title":"EMBO Rep"},{"issue":"4","key":"4032_CR32","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1159\/000489208","volume":"46","author":"P Li","year":"2018","unstructured":"Li P, Yang X, Yuan W, Yang C, Zhang X, Han J et al (2018) CircRNA-Cdr1as exerts anti-oncogenic functions in bladder cancer by sponging MicroRNA-135a. Cell Physiol Biochem 46(4):1606\u20131616","journal-title":"Cell Physiol Biochem"},{"key":"4032_CR33","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.2147\/CMAR.S245233","volume":"12","author":"C Li","year":"2020","unstructured":"Li C, Fu X, He H, Chen C, Wang Y, He L (2020) The biogenesis, functions, and roles of circRNAs in bladder cancer. Cancer Manag Res 12:3673\u201389","journal-title":"Cancer Manag Res"},{"key":"4032_CR34","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y et al (2023) Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updates 68:100938","journal-title":"Drug Resist Updates"},{"key":"4032_CR35","doi-asserted-by":"publisher","first-page":"117027","DOI":"10.1016\/j.biopha.2024.117027","volume":"177","author":"Q Li","year":"2024","unstructured":"Li Q, Zhang Y, Jin P, Chen Y, Zhang C, Geng X et al (2024a) New insights into the potential of exosomal circular RNAs in mediating cancer chemotherapy resistance and their clinical applications. Biomed Pharmacother 177:117027","journal-title":"Biomed Pharmacother"},{"key":"4032_CR36","doi-asserted-by":"publisher","first-page":"112485","DOI":"10.1016\/j.intimp.2024.112485","volume":"137","author":"K Li","year":"2024","unstructured":"Li K, Lv J, Wang J, Wei Y, Zhang Y, Lin J et al (2024b) CircZNF609 inhibited bladder cancer immunotherapy sensitivity via enhancing fatty acid uptake through IGF2BP2\/CD36 pathway. Int Immunopharmacol 137:112485","journal-title":"Int Immunopharmacol"},{"key":"4032_CR37","doi-asserted-by":"publisher","first-page":"606485","DOI":"10.3389\/fonc.2020.606485","volume":"10","author":"Z Liang","year":"2021","unstructured":"Liang Z, Guo W, Fang S, Zhang Y, Lu L, Xu W et al (2021) CircRNAs: emerging bladder cancer biomarkers and targets. Front Oncol 10:606485","journal-title":"Front Oncol"},{"key":"4032_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jare.2021.11.010","volume":"39","author":"S Liu","year":"2022","unstructured":"Liu S, Chen X, Lin T (2022a) Emerging strategies for the improvement of chemotherapy in bladder cancer: current knowledge and future perspectives. J Adv Res 39:187\u2013202","journal-title":"J Adv Res"},{"issue":"12","key":"4032_CR39","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41417-022-00506-w","volume":"29","author":"Q Liu","year":"2022","unstructured":"Liu Q, You B, Meng J, Huang C-P, Dong G, Wang R et al (2022b) Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2\/circ_0001005\/PD-L1 signaling. Cancer Gene Ther 29(12):1988\u20132000","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"4032_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3892\/ijo.2024.5684","volume":"65","author":"Y Liu","year":"2024","unstructured":"Liu Y, Liang J, Zhang Y, Guo Q (2024) Drug resistance and tumor immune microenvironment: an overview of current understandings. Int J Oncol 65(4):96","journal-title":"Int J Oncol"},{"issue":"6","key":"4032_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.clon.2021.03.001","volume":"33","author":"T Lodhi","year":"2021","unstructured":"Lodhi T, Song YP, West C, Hoskin P, Choudhury A (2021) Hypoxia and its modification in bladder cancer: current and future perspectives. Clin Oncol 33(6):376\u2013390","journal-title":"Clin Oncol"},{"key":"4032_CR42","doi-asserted-by":"publisher","first-page":"659166","DOI":"10.3389\/fonc.2021.659166","volume":"11","author":"J Lv","year":"2021","unstructured":"Lv J, Zhou Z, Wang J, Yang X, Yu H, Han J et al (2021) CircFAM114A2 promotes cisplatin sensitivity via miR-222-3p\/P27 and miR-146a-5p\/P21 cascades in urothelial carcinoma. Front Oncol 11:659166","journal-title":"Front Oncol"},{"issue":"1","key":"4032_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13046-023-02614-3","volume":"42","author":"J Lv","year":"2023","unstructured":"Lv J, Li K, Yu H, Han J, Zhuang J, Yu R et al (2023) HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1\/PKM2 pathway. J Exp Clin Cancer Res 42(1):41","journal-title":"J Exp Clin Cancer Res"},{"key":"4032_CR44","doi-asserted-by":"publisher","first-page":"111164","DOI":"10.1016\/j.cellsig.2024.111164","volume":"119","author":"F Lyu","year":"2024","unstructured":"Lyu F, Huang S, Yan Z, He Q, Liu C, Cheng L et al (2024) CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway. Cell Signal 119:111164","journal-title":"Cell Signal"},{"issue":"1","key":"4032_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.critrevonc.2015.05.005","volume":"96","author":"F Massari","year":"2015","unstructured":"Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D et al (2015) Emerging concepts on drug resistance in bladder cancer: implications for future strategies. Crit Rev Oncol Hematol 96(1):81\u201390","journal-title":"Crit Rev Oncol Hematol"},{"key":"4032_CR46","doi-asserted-by":"publisher","first-page":"216023","DOI":"10.1016\/j.canlet.2022.216023","volume":"554","author":"X Meng","year":"2023","unstructured":"Meng X, Xiao W, Sun J, Li W, Yuan H, Yu T et al (2023) CircPTK2\/PABPC1\/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. Cancer Lett 554:216023","journal-title":"Cancer Lett"},{"key":"4032_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-031-79177-2_4","volume-title":"Exosomes and MicroRNAs in Biomedical Science","author":"H Mirzaei","year":"2022","unstructured":"Mirzaei H, Rahimian N, Mirzaei HR, Nahand JS, Hamblin MR (2022) MicroRNAs as Biomarkers. In: Mirzaei H, Rahimian N, Mirzaei HR, Nahand JS, Hamblin MR (eds) Exosomes and MicroRNAs in Biomedical Science. Springer International Publishing, Cham, pp 69\u201377"},{"issue":"2","key":"4032_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.52679\/tabcj.2020.0010","volume":"1","author":"R Mishra","year":"2020","unstructured":"Mishra R (2020) Bio-genesis and deregulation of circular ribonucleic acid and their role in human cancer. Appl Biol Chem J 1(2):83\u201394","journal-title":"Appl Biol Chem J"},{"issue":"6","key":"4032_CR49","doi-asserted-by":"publisher","first-page":"189189","DOI":"10.1016\/j.bbcan.2024.189189","volume":"1879","author":"S Mohamadi","year":"2024","unstructured":"Mohamadi S, Mehrasa P, Mehramuz B, Kobravi S, Taghizadieh M, Salmaninejad A et al (2024) The tumor microenvironment\u2019s gambit: exosomal pawns on the board of head and neck cancer. Biochim Biophys Acta Rev Cancer. 1879(6):189189","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"4032_CR50","doi-asserted-by":"publisher","first-page":"709324","DOI":"10.3389\/fphar.2021.709324","volume":"12","author":"Q Mu","year":"2021","unstructured":"Mu Q, Lv Y, Luo C, Liu X, Huang C, Xiu Y et al (2021) Research progress on the functions and mechanism of circRNA in cisplatin resistance in tumors. Front Pharmacol 12:709324","journal-title":"Front Pharmacol"},{"key":"4032_CR51","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3389\/fmicb.2020.01853","volume":"11","author":"JS Nahand","year":"2020","unstructured":"Nahand JS, Jamshidi S, Hamblin MR, Mahjoubin-Tehran M, Vosough M, Jamali M et al (2020) Circular RNAs: new epigenetic signatures in viral infections. Front Microbiol 11:1853","journal-title":"Front Microbiol"},{"key":"4032_CR52","doi-asserted-by":"publisher","first-page":"963877","DOI":"10.3389\/fimmu.2022.963877","volume":"13","author":"S Pan","year":"2022","unstructured":"Pan S, Li S, Zhan Y, Chen X, Sun M, Liu X et al (2022) Immune status for monitoring and treatment of bladder cancer. Front Immunol 13:963877","journal-title":"Front Immunol"},{"issue":"12","key":"4032_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/carcin\/bgad065","volume":"44","author":"J Pan","year":"2023","unstructured":"Pan J, Xie X, Sheng J, Ju C, Sun S, Cui F et al (2023) Construction and identification of lncRNA\/circRNA-coregulated ceRNA networks in gemcitabine-resistant bladder carcinoma. Carcinogenesis 44(12):847\u2013858","journal-title":"Carcinogenesis"},{"issue":"38","key":"4032_CR54","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1038\/s41388-023-02780-w","volume":"42","author":"G Pisignano","year":"2023","unstructured":"Pisignano G, Michael DC, Visal TH, Pirlog R, Ladomery M, Calin GA (2023) Going circular: history, present, and future of circRNAs in cancer. Oncogene 42(38):2783\u20132800","journal-title":"Oncogene"},{"key":"4032_CR55","doi-asserted-by":"crossref","unstructured":"Qayoom H, Mehraj U, Aisha S, Sofi S, Mir MA (2021) Integrating immunotherapy with chemotherapy: a new approach to drug repurposing: IntechOpen London","DOI":"10.5772\/intechopen.100183"},{"key":"4032_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-0716-2823-2_2","volume-title":"MicroRNA Profiling: Methods and Protocols","author":"N Rahimian","year":"2023","unstructured":"Rahimian N, Nahand JS, Hamblin MR, Mirzaei H (2023) Exosomal MicroRNA profiling. In: Rani S (ed) MicroRNA Profiling: Methods and Protocols. Springer, US, New York, pp 13\u201347"},{"issue":"1","key":"4032_CR57","first-page":"69","volume":"4","author":"G Rajendran","year":"2021","unstructured":"Rajendran G, Taylor JA III, Woolbright BL (2021) Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer. Cancer Drug Resist 4(1):69","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"4032_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME et al (2017) Bladder cancer. Nat Rev Dis Primers 3(1):1\u201319","journal-title":"Nat Rev Dis Primers"},{"key":"4032_CR59","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fphar.2018.00584","volume":"9","author":"F Shao","year":"2018","unstructured":"Shao F, Huang M, Meng F, Huang Q (2018) Circular RNA signature predicts gemcitabine resistance of pancreatic ductal adenocarcinoma. Front Pharmacol 9:584","journal-title":"Front Pharmacol"},{"key":"4032_CR60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.10.006","volume":"468","author":"Z Shen","year":"2020","unstructured":"Shen Z, Zhou L, Zhang C, Xu J (2020) Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Lett 468:88\u2013101","journal-title":"Cancer Lett"},{"issue":"1","key":"4032_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-024-01968-2","volume":"23","author":"X Shi","year":"2024","unstructured":"Shi X, Pang S, Zhou J, Yan G, Gao R, Wu H et al (2024) Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs. Mol Cancer 23(1):52","journal-title":"Mol Cancer"},{"issue":"1","key":"4032_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41585-024-00901-y","volume":"22","author":"DJ Smith","year":"2025","unstructured":"Smith DJ, Lunj S, Adamson AD, Nagarajan S, Smith TA, Reeves KJ et al (2025) CRISPR\u2013Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer. Nat Rev Urol 22(1):55\u201365","journal-title":"Nat Rev Urol"},{"key":"4032_CR63","doi-asserted-by":"publisher","first-page":"809620","DOI":"10.3389\/fcell.2021.809620","volume":"9","author":"Y Song","year":"2022","unstructured":"Song Y, Du Y, Qin C, Liang H, Yang W, Lin J et al (2022) Gemcitabine-resistant biomarkers in bladder cancer are associated with tumor-immune microenvironment. Front Cell Dev Biol 9:809620","journal-title":"Front Cell Dev Biol"},{"issue":"23","key":"4032_CR64","doi-asserted-by":"publisher","first-page":"10826","DOI":"10.18632\/aging.102464","volume":"11","author":"Y Su","year":"2019","unstructured":"Su Y, Du Z, Zhong G, Ya Y, Bi J, Shi J et al (2019a) circ5912 suppresses cancer progression via inducing MET in bladder cancer. Aging 11(23):10826","journal-title":"Aging"},{"issue":"2","key":"4032_CR65","doi-asserted-by":"publisher","first-page":"441","DOI":"10.7150\/ijbs.26826","volume":"15","author":"Y Su","year":"2019","unstructured":"Su Y, Yang W, Jiang N, Shi J, Chen L, Zhong G et al (2019b) Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance. Int J Biol Sci 15(2):441","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4032_CR66","first-page":"1349","volume":"47","author":"J Sun","year":"2019","unstructured":"Sun J, Zhang H, Tao D, Xie F, Liu F, Gu C et al (2019) CircCDYL inhibits the expression of C-MYC to suppress cell growth and migration in bladder cancer. Artif Nanomed Biotechnol 47(1):1349\u20131356","journal-title":"Artif Nanomed Biotechnol"},{"issue":"18","key":"4032_CR67","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.3390\/cancers13184618","volume":"13","author":"K Sun","year":"2021","unstructured":"Sun K, Wang D, Yang BB, Ma J (2021) The emerging functions of circular RNAs in bladder cancer. Cancers 13(18):4618","journal-title":"Cancers"},{"issue":"1","key":"4032_CR68","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12885-022-09419-1","volume":"22","author":"M Sun","year":"2022","unstructured":"Sun M, Liu X, Zhao W, Zhang B, Deng P (2022) Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p. BMC Cancer 22(1):313","journal-title":"BMC Cancer"},{"issue":"15","key":"4032_CR69","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s41388-023-02637-2","volume":"42","author":"J Sun","year":"2023","unstructured":"Sun J, Zhang H, Wei W, Xiao X, Huang C, Wang L et al (2023) Regulation of CD8+ T cells infiltration and immunotherapy by circMGA\/HNRNPL complex in bladder cancer. Oncogene 42(15):1247\u20131262","journal-title":"Oncogene"},{"issue":"1","key":"4032_CR70","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s10020-024-00839-2","volume":"30","author":"M Szelest","year":"2024","unstructured":"Szelest M, Giannopoulos K (2024) Biological relevance of alternative splicing in hematologic malignancies. Mol Med 30(1):62","journal-title":"Mol Med"},{"key":"4032_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-981-19-6442-8_1","volume-title":"Gallbladder cancer: current treatment options","author":"M Taghizadieh","year":"2023","unstructured":"Taghizadieh M, Seyedi M, Azhdari S, Dashti F, Mirazimi SMA, Baghi HB et al (2023) Gallbladder cancer: current treatment options and therapeutics. In: Kumar Shukla V, Pandey M, Dixit R (eds) Gallbladder cancer: current treatment options. Springer Nature Singapore, Singapore, pp 3\u201330"},{"issue":"4","key":"4032_CR72","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.18632\/aging.102816","volume":"12","author":"T Tao","year":"2020","unstructured":"Tao T, Yuan S, Liu J, Shi D, Peng M, Li C et al (2020) Cancer stem cell-specific expression profiles reveal emerging bladder cancer biomarkers and identify circRNA_103809 as an important regulator in bladder cancer. Aging (Albany NY) 12(4):3354","journal-title":"Aging (Albany NY)"},{"key":"4032_CR73","doi-asserted-by":"publisher","first-page":"1235884","DOI":"10.3389\/fimmu.2023.1235884","volume":"14","author":"J van Dorp","year":"2023","unstructured":"van Dorp J, van der Heijden MS (2023) The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Front Immunol 14:1235884","journal-title":"Front Immunol"},{"issue":"5","key":"4032_CR74","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41419-021-03743-3","volume":"12","author":"L Verduci","year":"2021","unstructured":"Verduci L, Tarcitano E, Strano S, Yarden Y, Blandino G (2021) CircRNAs: role in human diseases and potential use as biomarkers. Cell Death Dis 12(5):468","journal-title":"Cell Death Dis"},{"issue":"12","key":"4032_CR75","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41374-022-00826-3","volume":"102","author":"L Wang","year":"2022","unstructured":"Wang L, Wu S, He H, Ai K, Xu R, Zhang L et al (2022) CircRNA-ST6GALNAC6 increases the sensitivity of bladder cancer cells to erastin-induced ferroptosis by regulating the HSPB1\/P38 axis. Lab Invest 102(12):1323\u20131334","journal-title":"Lab Invest"},{"issue":"4","key":"4032_CR76","first-page":"497","volume":"65","author":"O Wawrzyniak","year":"2018","unstructured":"Wawrzyniak O, Zar\u0119bska \u017b, Rolle K, Gotz-Wi\u0119ckowska A (2018) Circular and long non-coding RNAs and their role in ophthalmologic diseases. Acta Biochim Pol 65(4):497\u2013508","journal-title":"Acta Biochim Pol"},{"issue":"24","key":"4032_CR77","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-21-1518","volume":"81","author":"W Wei","year":"2021","unstructured":"Wei W, Sun J, Zhang H, Xiao X, Huang C, Wang L et al (2021) Circ0008399 interaction with WTAP promotes assembly and activity of the m6A methyltransferase complex and promotes cisplatin resistance in bladder cancer. Can Res 81(24):6142\u20136156","journal-title":"Can Res"},{"issue":"1","key":"4032_CR78","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-023-02932-6","volume":"43","author":"W Wei","year":"2024","unstructured":"Wei W, Liu K, Huang X, Tian S, Wang H, Zhang C et al (2024) EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance. J Exp Clin Cancer Res 43(1):2","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"4032_CR79","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.tcb.2019.12.004","volume":"30","author":"M-S Xiao","year":"2020","unstructured":"Xiao M-S, Ai Y, Wilusz JE (2020) Biogenesis and functions of circular RNAs come into focus. Trends Cell Biol 30(3):226\u2013240","journal-title":"Trends Cell Biol"},{"issue":"7","key":"4032_CR80","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.7150\/jca.39722","volume":"11","author":"F Xie","year":"2020","unstructured":"Xie F, Zhao N, Zhang H, Xie D (2020a) Circular RNA CircHIPK3 promotes gemcitabine sensitivity in bladder cancer. J Cancer 11(7):1907\u20131912","journal-title":"J Cancer"},{"key":"4032_CR81","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.lfs.2019.117252","volume":"254","author":"Y Xie","year":"2020","unstructured":"Xie Y, Yuan X, Zhou W, Kosiba AA, Shi H, Gu J et al (2020b) The circular RNA HIPK3 (circHIPK3) and its regulation in cancer progression. Life Sci 254:117252","journal-title":"Life Sci"},{"issue":"3","key":"4032_CR82","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/jcb.29481","volume":"121","author":"Y Xing","year":"2020","unstructured":"Xing Y, Zha WJ, Li XM, Li H, Gao F, Ye T et al (2020) Circular RNA circ-Foxo3 inhibits esophageal squamous cell cancer progression via the miR-23a\/PTEN axis. J Cell Biochem 121(3):2595\u20132605","journal-title":"J Cell Biochem"},{"issue":"1","key":"4032_CR83","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","volume":"5","author":"J Xu","year":"2020","unstructured":"Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X et al (2020) CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther 5(1):298","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4032_CR84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s11658-024-00543-3","volume":"29","author":"C Xu","year":"2024","unstructured":"Xu C, Zhou J, Zhang X, Kang X, Liu S, Song M et al (2024) N6-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges. Cell Mol Biol Lett 29(1):28","journal-title":"Cell Mol Biol Lett"},{"issue":"2","key":"4032_CR85","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/cas.15213","volume":"113","author":"H Yamauchi","year":"2022","unstructured":"Yamauchi H, Nishimura K, Yoshimi A (2022) Aberrant RNA splicing and therapeutic opportunities in cancers. Cancer Sci 113(2):373\u2013381","journal-title":"Cancer Sci"},{"issue":"4","key":"4032_CR86","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1878-0261.12032","volume":"11","author":"M Yang","year":"2017","unstructured":"Yang M, Liu P, Wang K, Glorieux C, Hu Y, Wen S et al (2017) Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. Mol Oncol 11(4):358\u2013372","journal-title":"Mol Oncol"},{"issue":"1","key":"4032_CR87","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-018-0771-7","volume":"17","author":"C Yang","year":"2018","unstructured":"Yang C, Yuan W, Yang X, Li P, Wang J, Han J et al (2018) Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17\/miR-224 and regulating p21, PTEN expression. Mol Cancer 17(1):19","journal-title":"Mol Cancer"},{"key":"4032_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01300-8","volume":"20","author":"X Yang","year":"2021","unstructured":"Yang X, Ye T, Liu H, Lv P, Duan C, Wu X et al (2021a) Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Mol Cancer 20:1\u201325","journal-title":"Mol Cancer"},{"issue":"1","key":"4032_CR89","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-020-01300-8","volume":"20","author":"X Yang","year":"2021","unstructured":"Yang X, Ye T, Liu H, Lv P, Duan C, Wu X et al (2021b) Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Mol Cancer 20(1):4","journal-title":"Mol Cancer"},{"issue":"3","key":"4032_CR90","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.ymthe.2022.01.022","volume":"30","author":"C Yang","year":"2022","unstructured":"Yang C, Wu S, Mou Z, Zhou Q, Dai X, Ou Y et al (2022) Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments. Mol Ther 30(3):1054\u20131070","journal-title":"Mol Ther"},{"issue":"1","key":"4032_CR91","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12929-019-0523-z","volume":"26","author":"C-Y Yu","year":"2019","unstructured":"Yu C-Y, Kuo H-C (2019) The emerging roles and functions of circular RNAs and their generation. J Biomed Sci 26(1):29","journal-title":"J Biomed Sci"},{"issue":"7","key":"4032_CR92","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/1878-0261.12523","volume":"13","author":"W Yuan","year":"2019","unstructured":"Yuan W, Zhou R, Wang J, Han J, Yang X, Yu H et al (2019) Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition. Mol Oncol 13(7):1559\u20131576","journal-title":"Mol Oncol"},{"key":"4032_CR93","doi-asserted-by":"crossref","unstructured":"Zaiou M (2019) Circular RNAs as potential biomarkers and therapeutic targets for metabolic diseases. Reviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders, pp 177\u201391","DOI":"10.1007\/978-3-030-12668-1_10"},{"key":"4032_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-020-01054-3","volume":"15","author":"AS Zangouei","year":"2020","unstructured":"Zangouei AS, Rahimi HR, Mojarrad M, Moghbeli M (2020) Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells. Diagn Pathol 15:1\u201313","journal-title":"Diagn Pathol"},{"issue":"1","key":"4032_CR95","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-021-01360-4","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xiao X, Wei W, Huang C, Wang M, Wang L et al (2021a) CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutS\u03b1\/ATM-p73 axis in bladder cancer. Mol Cancer 20(1):70","journal-title":"Mol Cancer"},{"key":"4032_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01360-4","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xiao X, Wei W, Huang C, Wang M, Wang L et al (2021b) CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutS\u03b1\/ATM-p73 axis in bladder cancer. Mol Cancer 20:1\u201320","journal-title":"Mol Cancer"},{"key":"4032_CR97","doi-asserted-by":"publisher","first-page":"096368972311658","DOI":"10.1177\/09636897231165874","volume":"32","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li Z, Zhang Y, Shen C, Zhang Z, Ren X et al (2023) circSOBP inhibits bladder cancer proliferation and metastasis by regulating the miR-200a-3p\/PTEN axis and participating in the immune response. Cell Transplant 32:09636897231165874","journal-title":"Cell Transplant"},{"issue":"16","key":"4032_CR98","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.3390\/ijms20163926","volume":"20","author":"X Zhao","year":"2019","unstructured":"Zhao X, Cai Y, Xu J (2019) Circular RNAs: biogenesis, mechanism, and function in human cancers. Int J Mol Sci 20(16):3926","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4032_CR99","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5483\/BMBRep.2020.53.2.059","volume":"53","author":"C Zhuang","year":"2020","unstructured":"Zhuang C, Huang X, Yu J, Gui Y (2020) Circular RNA hsa_circ_0075828 promotes bladder cancer cell proliferation through activation of CREB1. BMB Rep 53(2):82","journal-title":"BMB Rep"},{"key":"4032_CR100","doi-asserted-by":"publisher","first-page":"113762","DOI":"10.1016\/j.intimp.2024.113762","volume":"145","author":"J Zhuang","year":"2025","unstructured":"Zhuang J, Zhou M, Yu H, Zhou R, Bai K, Lv J et al (2025) CircFAM64A(3) promoted bladder cancer proliferation and inhibited CD8 + T cell via sponging to miR-149-5p and activated IL-6\/JAK\/STAT pathway. Int Immunopharmacol 145:113762","journal-title":"Int Immunopharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04032-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:02:39Z","timestamp":1758301359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04032-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["4032"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04032-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In preparing this manuscript, the authors utilized DeepAI\u2019s chat GPT to refine their writing and improve the document's readability and language. After leveraging this tool, the authors thoroughly reviewed and modified the content as necessary, assuming full responsibility for the final published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}